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ABSTRACT 
After natural menopause in women, androstenedione becomes the 
primary hormone secreted by the residual follicle deplete ovaries. Two 
independent studies, in rodents that had undergone ovarian follicular 
depletion, found that higher serum androstenedione levels correlated with 
increased working memory errors.  This led to the hypothesis that 
androstenedione impairs memory.  The current study directly tested this 
hypothesis, examining the cognitive effects of androstenedione 
administration in a rodent model.  Middle-aged ovariectomized rats 
received vehicle or one of two doses of androstenedione (4 or 8 mg/kg 
daily).  Rats were tested on a spatial working and reference memory maze 
battery including the water radial arm maze, Morris maze, and delay-
match-to-sample task.  Results showed that androstenedione at the 
highest dose impaired reference memory and working memory, including 
ability to maintain performance as memory demand was elevated. The 
latter was true for both high temporal demand memory retention of one 
item of spatial information, as well as the ability to handle multiple items of 
spatial working memory information.  Glutamic acid decarboxylase (GAD) 
levels were measured in multiple brain regions to determine whether the 
gamma-aminobutyric acid (GABA) system mediates androstenedione’s 
cognitive impairments.  Results showed that higher entorhinal cortex GAD 
levels were correlated with poorer Morris maze performance, regardless of 
androstenedione treatment.  These findings suggest that 
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androstenedione, the main hormone produced by the follicle deplete 
ovary, is detrimental to spatial learning, reference memory, and working 
memory, and that spatial reference memory performance might be related 
to the GABAergic system.   
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Introduction 
Clinical evidence suggests that cognitive outcomes following 
ovarian hormone loss differ depending upon whether menopause is 
surgical or transitional.  Research has shown that surgically menopausal 
women exhibited lower memory scores relative to naturally menopausal 
women, and age of oophorectomy and greater years since surgery 
correlated with poorer performance (Nappi et al., 1999; Farrag et al., 
2002).  Researching menopause in the rodent model has been difficult 
due to the differences in the mechanisms responsible for the age-related 
reproductive senescence and the hormonal milieu that follows (Meites & 
Lu, 1994; Timaras et al., 1995). 
In the last decade, a rodent model of menopause has been 
developed. It has been shown that the industrial chemical 4-
vinylcyclohexene diepoxide (VCD) produces follicular depletion in rodents 
(Mayer et al., 2002).  VCD selectively destroys primordial and primary 
follicles, resulting in follicular depletion and ovarian failure (Mayer et al., 
2004).  This results in a follicle deplete post-menopausal ovary, and a 
hormone milieu similar to that seen in naturally menopausal women 
(Timaras et al., 1995) .  The interstitial ovarian tissue yields decreased 
progesterone and androstenedione, and because estrogens become 
deplete, this creates in an androgen rich milieu (Mayer et al., 2004). Using 
this VCD model, in middle-aged female rats, we recently showed that 
retention of the follicle deplete ovary after transitional menopause 
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negatively impacts memory (Acosta et al., 2009a). Specifically, removal of 
residual ovaries after transitional follicular depletion improved cognition 
relative to retention of residual ovaries (Acosta et al., 2009a), as rats that 
underwent VCD-induced transitional menopause followed by ovariectomy 
(OVX) showed better cognitive performance compared to VCD 
menopausal rats that remained ovary-intact.  The only difference between 
these groups was presence of follicle deplete ovaries.  Circulating 
androstenedione levels related to cognitive detriment, with more working 
memory errors correlating with higher serum androstenedione levels.  
These findings are especially noteworthy given that androstenedione is 
the main hormone released by the post-menopausal ovary, and becomes 
the main source of plasma estrogens after menopause due to 
aromatization (Grodin et al., 1973).  
If androstenedione can in fact impair memory, as our two prior 
correlations between cognitive performance and circulating 
androstenedione levels indicate (Acosta et al., 2009b; Acosta et al., 2010), 
administering androstenedione at doses that correspond to higher 
physiological levels to the OVX rat should impair cognitive performance. 
Here, we directly tested the hypothesis that such androstenedione 
administration impairs spatial working and reference memory.  Two doses 
of exogenous androstenedione were administered to middle-aged 
surgically menopausal (OVX) rats, with doses based on previous studies 
(Lea & Flanagan, 1998; Sprando et al., 2004) showing physiological levels 
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of androstenedione comparable to those correlating with poor cognitive 
performance in Acosta et al. (2009a). We tested androstenedione’s impact 
on cognition using a battery of tasks tapping into several memory domains 
including, the water radial-arm maze (WRAM) which assessed working 
and reference memory and incorporated memory load increase across 
trials, the Morris water maze (MM) which tested spatial reference memory, 
the delayed-match-to-sample three choice task (DMS) which examined 
working memory, and the elevated plus maze (EPM) which assessed 
anxiety-like behavior.  The WRAM and DMS included retention delays 
spanning hours, to evaluate high demand memory retention.  Additionally, 
androstenedione was measured and correlated with memory measures, 
as done previously (Acosta et al., 2009a).  
We also sought to evaluate whether the GABAergic system plays a 
role in the relationship between androstenedione and memory. Research 
suggests the GABAA receptor (GABAA-R) modulates cognition. GABAA-R 
antagonists enhances memory, and GABAA agonists impair memory 
(Yonkov & Georgiev, 1985; Yonkov et al., 1987; Brioni et al., 1989; 
Castellano & McGaugh, 1990; Castellano et al., 1993; Zarrindast et al., 
2004).  Further, several androgens have been shown to have effects on 
GABAA receptors.  For example, dehydroepiandrosterone can act as a 
GABAAR negative allosteric modulator (Birzniece et al., 2006), and has 
been shown to improve memory in middle-aged and aged mice (Flood & 
Roberts, 1988; Farr et al., 2004).  Further supporting the hypothesis that 
 4 
 
androstenedione might impair cognition via GABAAR, androstanediol has 
been shown to be a positive allosteric modulator of GABAAR (Reddy & 
Jian, 2010). To assess androstenedione’s impact on the GABAergic 
system, we measured levels of glutamic acid decarboxylase (GAD), the 
synthesizing enzyme and rate limiting step of GABA production, in multiple 
cognitive brain regions after maze testing concluded. 
 
Methods 
Subjects 
 Twenty-six fourteen month-old Fischer 344 female rats born and 
raised at the aging colony of the National Institute on Aging at Harlan 
Laboratories (Indianapolis, IN) were used.  Upon arrival, rats were pair 
housed, acclimated for two weeks before surgery, had access to food and 
water ad-lib and were maintained on a 12-hour light/dark cycle at the 
Arizona State University animal facility.  All procedures were approved by 
the local IACUC committee and adhered to NIH standards. 
 
Ovariectomy (OVX) and hormone treatment 
 Approximately two weeks before behavioral testing, all rats 
received OVX under isofluorane inhalation.  OVX consisted of bilateral 
dorsolateral incisions in the skin and peritoneum, the ovaries and tips of 
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the uterine horns were ligatured and removed, and muscle and skin were 
sutured.  After surgery, rats received Rimadyl (5mg/mL/kg) for pain and 
saline (2mL) to prevent dehydration.   
 Rats were randomly assigned to one of three treatment groups: 
Vehicle (n=10), Androstenedione Low (n=8), and Androstenedione High 
(n=8) (Steraloids, Newport, RI, USA). Vehicle-treated animals received 0.5 
mL of polyethylene glycol (PEG) (Sigma-Aldrich, St. Louis, MO, USA) 
only. The Androstenedione Low group was given 4mg/kg daily, and the 
Androstenedione High group was given 8mg/kg daily. Doses were based 
on previous literature (Lea & Flanagan, 1998; Sprando et al., 2004), 
showing desired serum ranges of androstenedione comparable to the 
levels found in Acosta et. al (2009a) that were correlated with greater 
errors on a working memory task. Hormone or vehicle treatment began 
two days after surgery (12 days before behavioral testing ensued) and 
continued until sacrifice (See Figure 1 for timetable).  The assigned 
substrate was administered daily between 0730 and 0830 via 
subcutaneous injection into the scruff of the neck.  All hormone doses 
were dissolved in polyethylene glycol (PEG) so that each dose was given 
in 0.5mL PEG.  
 
 
Vaginal smears and uterine weights 
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 Vaginal smears were taken 8, 9, 10, 11, 28, and 44 days after OVX; 
hormone administration began 2 days after OVX, and thus hormone was 
being administered during the time when smears were done.  Smears 
were classified as proestrus, estrous, metestrus, or diestrus, per prior 
protocols (Goldman et al., 2007; Acosta et al., 2009b). Prior studies have 
shown that androgens stimulate the uterus and lead to increased uterine 
weight (Ruizeveld de Winter et al., 1991; Horie et al., 1992). Thus, to 
further verify androstenedione’s effects on uterine tissues, at sacrifice the 
uteri of all subjects were removed, trimmed of visible fat, and immediately 
weighed (wet weight). 
 
Water radial-arm maze (WRAM) 
  Subjects were tested for 13 days on the eight-arm win-shift WRAM 
(Figure 2a) to evaluate spatial working and reference memory, including 
performance as working memory load increased, as described previously 
(Bimonte & Denenberg, 1999). The black plexiglass maze was filled with 
water made opaque with black non-toxic paint.  The temperature of the 
water was 18°-19°C.  The maze contained escape platforms hidden under 
the water surface in the ends of four of eight arms (each arm was 38.1 cm 
x 12.7 cm).  Each subject was assigned different platform locations that 
remained constant throughout the 13 days of testing.  The subjects were 
released from the start arm and had 3 minutes to locate a platform.  Once 
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a platform was found, the subject remained on it for 15 seconds, and was 
then returned to its heated cage for a 30 second inter-trial interval (ITI) 
until its next trial.  During the interval, the just located platform was 
removed from the maze and the water was stirred with a net to collect 
fecal boli and bedding.  The animal was then placed again into the start 
alley, which remained constant throughout testing, and allowed to locate 
another platform. An arm entry was counted when the tip of a rat’s snout 
reached a mark delineated on the outside of the arm and not visible from 
the inside of the maze (11cm into the arm). Orthogonal measures of 
working and reference memory errors were quantified as done previously 
in WRAM studies (Bimonte et al., 2000).  Working memory correct (WMC) 
errors were the number of first and repeat entries into an arm that 
previously contained a platform that session.  Reference memory (RM) 
errors were the number of first entries into an arm that never contained a 
platform.  Working memory incorrect (WMI) errors were repeat entries into 
reference memory arms.  For each animal a daily session consisted of 
four trials, with the number of platformed arms reduced by one on each 
subsequent trial.  Thus, the working memory system was increasingly 
taxed as trials progressed, allowing us to access performance as working 
memory load increased.  Each subject was given one session a day for 12 
consecutive days.  After 12 days at a 30 second ITI, a 6 hour ITI was 
initiated between trials 2 and 3.  
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 For WRAM analyses, for the three orthogonal measures of Working 
Memory Correct (WMC), Working Memory Incorrect (WMI), and 
Reference Memory (RM), learning across all testing days was evaluated in 
order to detect any Day x Treatment interactions.  Learning during the 
acquisition phase (Days 2-6) was evaluated.  Performance on the final two 
days of regular testing, Days 11-12, was evaluated at the highest working 
memory load (Trial 4), as this has revealed steroid hormone induced 
benefits, and age-related decrements, in our laboratory (Bimonte-Nelson 
et al., 2003a; Braden et al., 2010). For the 6 hour delay on Day 13, 
Treatment effects and Trial x Treatment interactions were analyzed for the 
post-delay trials (Trials 3 and 4) in order to detect potential delay-induced 
impairments across groups.  Errors committed on the post-day trials were 
compared to errors on the last day of regular testing, Day 12 (baseline), in 
order to detect impairing effects of a 6 hour delay vs. the 30 second ITI 
within group. 
 
Delay-match-to-sample (DMS) three choice task 
Animals were tested for 7 days on the four arm win-stay DMS 
(Figure 2b) to evaluate spatial working memory and short-term memory 
retention.  The black plexiglass maze (each arm was 38.1 cm x 12.7 cm) 
was filled with water made opaque with black non-toxic paint.  The 
temperature of the water was 18°-19°C.  Animals received 6 consecutive 
 9 
 
trials a day for 6 days.  The platform was located in a new arm each day, 
but remained in the same arm within a day for each subject. The drop off 
location varied for each trial, alternating between the three available arms 
two times each within a set of trials.  Trial one was the information trial 
informing the animal where the platform was for that day’s session, trial 
two was the working memory test trial and trials three through six were 
recent memory test trials (Frick et al., 1995). Rats were given 90 seconds 
to find the platform.  Once on the platform, the rat remained on it for 15 
seconds, followed by placement into a heated cage for a 30 second ITI.  
An arm entry was counted when the tip of a rat’s snout reached a mark 
delineated on the outside of the arm and not visible from the inside of the 
maze (11cm into the arm). First errors were first entries into an arm 
without a platform, and Repeat errors were repeat entries into an arm 
without a platform within the same trial. Thus, the dependent variables 
were First errors, Repeat errors, and Total (First + Repeat errors) errors, 
for Days 1-6, Trials 2-6 (Trial 1 was the information trial).  After 6 days of 
testing with a 30 second ITI, an increased time delay of 6 hours was given 
on day 7, between Trials 1 and 2, to assess delayed memory retention.  
Each error type was evaluated across all testing days in order to detect 
Day x Treatment interactions. Treatment effects were analyzed for the 
post-delay trial (Trial 2) in order to detect impairing effects of the delay 
within that day between treatment groups.  Errors committed on the post-
day trials were compared to errors on the last day of regular testing, Day 6 
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(baseline) in order to detect impairing effects of a 6 hour delay vs. the 30 
second ITI within treatment groups.   
 
Morris water maze (MM) 
 The MM maze (Figure 2c) was tested for six trials a day for 3 days 
using a tub (188 cm diameter) filled with black water made opaque using 
non-toxic paint.  The temperature of the water was 18°-19°C.  A hidden 
platform (10 cm wide) remained in a fixed location throughout testing, 
thereby testing spatial reference memory (Morris et al., 1982; Bimonte-
Nelson et al., 2006).  The subject was placed in the maze from the North, 
South, East, or West location (semi-randomly determined), and had 60 
seconds to locate the hidden platform, located inside the Northeast 
quadrant throughout testing.  Once the rat found the platform the trial was 
terminated.  After 15 seconds of platform time, the subject was placed into 
its heated cage until its next trial.  The approximate ITI was 15 minutes.  
To evaluate whether subjects localized the platform to the spatial location, 
after all test trials were completed on day 3, a 60 second probe trial was 
given whereby the platform was removed.  For each trial, a camera 
suspended above the maze tracked each rat’s path and a tracking system 
(Ethovision, Noldus Instruments, Leesburg, VA, USA) analyzed each rat’s 
tracing.   
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 MM performance was assessed by swim path distance (cm) to the 
platform.  For probe trial data, total percent distance in the previously 
platformed (target) quadrant was compared to that in the quadrant 
diagonally opposite to the platform.  Rats that learned the platform location 
were expected to swim the greatest distance in the target quadrant (Hyde 
et al., 2002; Talboom et al., 2008). 
 
Elevated plus maze (EPM) 
 Animals were tested on the EPM (Figure 2d) for one day, with a 5 
minute trial to evaluate anxiety, based on previously published protocols 
(Bellani et al., 2006; Huynh et al., 2011). The EPM consisted of four 
(50.8cm) contralateral arms (49.5 cm in length, 10.2cm in width) 
positioned in accordance to face North, South, East, and West.  The 
closed arms (East and West arms) had walls surrounding the perimeters 
(50.8 cm in height), while the open arms had no walls surrounding the arm 
floors.  Rats were placed into the center of the maze facing a randomly-
assigned closed arm and given 5 minutes to explore the environment.  For 
each trial, a camera suspended above the maze allowed for scoring on 
video.  Time spent in the open arms, frequency of open arm entrances, 
frequency of closed arm entries, and total fecal boli were quantified.  Time 
spent in the open arm, and open arm entrances, were defined as both 
front paws crossing into the open arm quadrant.  Closed arm entrances 
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were defined as when both front paws crossing into the closed arm 
quadrant.   At the end of the trial, the subject was placed back into its 
home cage, fecal boli were counted, and the maze was wiped clean with 
odor eliminator to clean any scents prior to the next trial.  An added 
measure of anxiety was calculated for EPM using the following equation, 
which unified all EPM parameters into one unified ratio.  Anxiety index 
values ranged from 0 to 1, with a higher value indicating increased 
anxiety.     
 
Visible platform maze 
 Since the MM, WRAM, and DMS rely on spatial navigation, it was 
necessary to confirm that all subjects had intact vision and could perform 
the procedural task components without difficulty.  A visible platform water 
escape task was used.  A rectangular tub (39 x 23 inches) was filled with 
clear water and a black platform (10 cm wide) was elevated above the 
water surface.  Opaque curtains covered extramaze cues.  The drop off 
location remained the same across trials, and the platform location for 
each trial varied in space semi-randomly.  Animals had to locate the 
platform protruding from the water, and were given six trials for one day.  
Performance was assessed by latency (s) to the platform.   
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Brain dissections 
 Two days after the conclusion of behavior testing, animals were 
anesthetized with isofluorane, decapitated, brains rapidly dissected, and 
tissues frozen.  Dissected tissues were stored in preweighed 
microcentrifuge tubes at -70°C until analysis.  Dissections were performed 
according to plate designations in Paxinos and Watson (Paxinos & 
Watson, 1998) and were as follows: frontal cortex (plates 5-14), cingulate 
cortex (plates 5-14), basal forebrain (plates 14-16), perirhinal cortex 
(plates 39-42), entorhinal cortex (plates 39-42), and CA1/CA2 region of 
the dorsal hippocampus (plates 33-35). For each brain the frontal cortex 
was taken first from the dorsal aspect of the intact brain.  Next, the 
cingulate cortex was taken with the longitudinal fissure as the medial 
border, and the medial border of the frontal cortex cut as the lateral 
border.  The brain was then cut in the coronal plane to obtain access to 
the basal forebrain.  For the basal forebrain, both medial septum and 
ventral diagonal band were included with the posterior landmark being the 
crossing point of the anterior commissure.  The brains were then cut in the 
coronal plane to obtain access to the last three brain regions.  For the 
CA1/CA2 region of the hippocampus, dentate gyrus and the alveus were 
excluded.  For the entorhinal cortex, the tissue was dissected from the 
same slice as the hippocampal sample, taking a 2- to 3-mm sample 
ventral to the hippocampus.  The perirhinal cortex was also collected from 
this same slice, taking a 2- to 3-mm sample around the perirhinal fissure. 
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Western blot analysis of GAD 65 + 67 
 GAD 65 + 67 protein expression levels were analyzed in frontal, 
cingulate, perirhinal and entorhinal cortices, and hippocampus, from the 
right hemisphere, as well as the basal forebrain.  Samples were sonicated 
in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% Na 
Deoxycholate, 50 mM Tris) equivalent to 10 times the weight of the 
sample and centrifuged at 10,000 RPM for 10 m at 4°C.  Protein 
concentrations were determined using BCA protein assays 
(ThermoFischer Scientific, Pittsburgh, PA, USA) and 10 µg of protein from 
each sample was run on a Run Blue 4-12% SDS gel, using the SureLock 
mini-cell (Invitrogen, Carlsbad, CA, USA).  Gels were counterbalanced by 
group and each region was run in two gels.  Half of each group was 
loaded onto a single gel, with two gels total for each brain region.  Proteins 
were transferred onto a PVDF membrane (Millipore, Bedford, MA, USA) 
and immunoblotting was performed with working dilutions of rabbit anti-
GAD 65 + 67 (ab11070) and rabbit anti-beta Actin (ab25894) primary 
antibodies (Abcam Inc., Cambridge, MA, USA).  Antibody dilutions were 
1:10,000 for GAD 65 + 67 and 1:1,000 for beta Actin primary antibodies.  
Membranes were then exposed to a peroxidase-conjugated goat anti-
rabbit secondary antibody, 1:20,000 dilution (111-035-003; Jackson 
Immuno Research, West Grove, PA, USA) and visualized using Pierce 
ECL (ThermoScientific, Rockford, IL, USA) on a Biospectrum Biochemi 
500 Imaging System (UVP, Upland, CA, USA).  Bands were identified as 
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the protein of interest, based on molecular weight, using Precision Plus 
Protein WesternC Standards (Bio Rad, Hercules, CA, USA). The density 
of GAD 65 + 67 and beta Actin (control protein) was then quantified using 
ImageJ software (Rasband, 1997-2004).  The dependent measure was a 
proportion of each subject’s GAD 65 + 67 density to their beta Actin 
density, brought to percent control of Vehicle subjects run on the same 
gel, per prior protocols (Pandey et al., 1999; Braden et al., 2010; Braden 
et al., 2011)  
 
Blood serum analysis 
 At the time of brain dissection, blood was collected via cardiac 
puncture (Vacutainer 367986, Becton Dickinson and Company, Franklin 
Lakes, NJ).  Blood was allowed to clot at 4°C and serum was collected 
after centrifugation (3220, 20min).  Serum was stored at -20°C until 
androstenedione assays were performed by the Core Endocrinology 
Laboratory at Pennsylvania State University College of Medicine.  
Serum levels of androstenedione were determined by iondinated RIA 
using reagents obtained from Siemens (Los Angeles, CA, USA) as done 
previously (Acosta et al., 2010).  The low-end sensitivity for this 
androstenedione method is 0.1 ng/ml. 
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Statistical analyses 
 Data were analyzed separately for each maze. WRAM, DMS, MM, 
and Visible Platform were first analyzed with a repeated measures 
ANOVA with Treatment as the between variable and Days and/or Trials as 
the within variable, as appropriate for the specific maze test.  EPM, GAD 
western blots, uterine weights, and serum analyses were analyzed using t-
tests with Treatment as the between variable.  Since our interest was to 
determine whether each dose of androstenedione enhanced or impaired 
performance relative to the Vehicle group, all of our comparisons were 
planned.  Any analysis comparing the Androstenedione Low to 
Androstenedione High group was done post hoc. 
 Correlations were used to examine relationships between 
androstenedione serum levels and behavioral results found to have 
significance using the ANOVA tests described above.  Circulating 
androstenedione levels were correlated with the following outcome 
variables: MM distance collapsed across all trials/days; DMS Total Errors 
postdelay; WRAM RM errors Days 2-6 Trial 2; and WRAM WMI errors 
Days 11-12 Trial 4.  Correlations were also used to examine relationships 
between GAD levels in multiple brain regions with the same behavioral 
results assessed in the androstenedione serum correlation analysis stated 
above. 
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Results 
Vaginal smears and uterine weights 
 During hormone treatment, all Vehicle and Androstenedione Low 
animals showed continuous diestrus smears, indicating lack of uterine 
stimulation, while Androstenedione High animals showed vaginal smears 
with an increased amount of cornified cells, indicating uterine stimulation. 
 Uteri of Androstenedione High animals weighed more than those of 
all other treatment groups (Androstenedione High vs. Vehicle: t16 = 2.47; 
P= 0.025; Androstenedione High vs. Androstenedione Low: t14 = 2.526; P 
= 0.024), as shown in Figure 3.   
 
Water radial-arm maze 
 There were no treatment main effects or interactions for WMC, 
WMI, RM during the acquisition phase (Days 2-6). However, upon 
inspection of the acquisition curves, we noted group differences for RM 
errors specific to Trial 2. RM errors on the WRAM maze are capped at a 
maximum of 4 errors each, with one entry per unplatformed arm counted 
as a reference memory error. Thus, committing errors on earlier trials 
limits the number of errors that can be made on later trials, and errors on 
earlier trials can be interpreted as earlier reference memory failure. In this 
regard, we analyzed Trial 2 alone post-hoc. The Androstenedione High 
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group committed more RM errors compared to both Vehicle (F1,16 = 6.974; 
P = 0.018) and  Androstenedione Low (F1,14 = 10.654; P = 0.006) groups 
(Figure 4a).  There were no treatment main effects or interactions for 
WMC or RM errors on Trial 4 during the final two days of testing (Days 11-
12).  There was a main effect for WMI errors on these final two days of 
testing, where the Androstenedione High group committed more WMI 
errors compared to both the Vehicle group (F1,16 = 6.673; P = 0.018) and 
Androstenedione Low group (F1,14 = 7.862; P = 0.014) (Figure 4b).  There 
were no treatment main effects or interactions for WMC, WMI, or RM for 
the 6-hour delay given on Day 13. 
 
Delay-match-to-sample three choice task 
 There were no treatment effects for Total Errors, First Errors, or 
Repeat Errors for Days 1-6.  The high dose androstenedione treatment 
impaired retention on the 6-hour delay manipulation given between trials 1 
and 2.  For the 6-hour delay given on day 7, Androstenedione High was 
the only group to commit significantly more Total Errors (Figure 5) (t7 = 
3.862; P = 0.006) and First Errors (t7 = 4.245; P = 0.004) compared to 
baseline (trial 2 on day 6).  Androstenedione Low and Vehicle groups 
were not impaired by the 6-hour delay, as they did not differ from their 
baseline scores to their delay scores.   
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Morris water maze 
 Figure 6 shows the mean distance to platform scores ± SE for each 
treatment group across the three days of MM testing, collapsed across 
trials.  Androstenedione treatment at the high dose impaired spatial 
reference memory; Androstenedione High rats swam a greater distance to 
the platform compared to Vehicle rats (F1,16 = 4.871;P = 0.042).  There 
was also a significant linear trend for dose of androstenedione (F1,2 = 
182.905; P = 0.047), with swim distance increasing as dose of 
androstenedione increased.  For the probe trial, each treatment group 
swam a higher percent swim distance in the target quadrant versus the 
opposite quadrant [Androstenedione High (t7 = 5.693; P = .001), 
Androstenedione Low (t7 = 5.565; P = .001), Vehicle (t9 = 10.336; P < 
.0001)], indicating that all groups, regardless of hormone status, localized 
the platform quadrant by the end of testing.  There were no group 
differences for platform crossings.   
 
Elevated plus maze 
 There were no treatment main effects for number of open arm 
entries (Figure 7a), number of closed arm entries (data not shown), 
amount of time spent in open arms (Figure 7b), and number of fecal boli 
(data not shown).  As well, there were no treatment main effects for the 
Anxiety Index (date not shown). 
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Visible platform 
 There were no Treatment main effects or interactions for latency on 
the visible platform task (Figure 8).  There was a Trial main effect (F2,5 = 
11.172; P < .0001), with Time decreasing across all trials of testing. By the 
last trial of testing, all subjects found the visible platform within 10 
seconds.  These data confirm visual and motor competence to perform 
swim maze tasks. 
 
Serum androstenedione levels 
 As expected, each Vehicle rat had undetectable levels of serum 
androstenedione.  The Androstenedione High group had higher serum 
androstenedione levels than the Vehicle group (t16 = 4.282; P = .0006), 
and the Androstenedione Low group had higher serum levels than the 
Vehicle group (t16 = 3.846; P = .0014) (Figure 9a). 
As shown in Figure 9b, replicating our prior correlations (Acosta et 
al., 2009a; Acosta et al., 2010), there was a significant correlation 
between androstenedione serum levels and WRAM WMI errors Days 11-
12 Trial 4 (r25 = .609; P = .0007), with higher androstenedione levels 
correlating with worse performance.  There were no significant 
correlations for androstenedione serum levels and MM distance collapsed 
across all trials/days; DMS Total errors post delay; and WRAM RM errors 
Days 2-6 Trial 2.   
 21 
 
Western Blots 
 There were no Treatment effects for GAD levels for the frontal 
cortex, cingulate cortex, basal forebrain, hippocampus, entorhinal cortex, 
or perirhinal cortex (Table 1).  There were also no Treatment effects for 
the loading control, beta actin.  For correlation analyses, all data points 
were centered to control for group differences, as done previously 
(Talboom et al., 2010); for more detailed methods and rationale of this 
procedure see (Hallahan & Rosenthal, 2000; Enders & Tofighi, 2007).  
There was a significant correlation between GAD levels in the entorhinal 
cortex and MM distance collapsed across all days and trials.  Animals that 
had higher GAD levels in the entorhinal cortex tended to swim a greater 
distance on the MM (r23 = .431; P = .036), as seen in Figure 10, 
suggesting that higher GAD levels in the entorhinal cortex are associated 
with poorer spatial reference memory performance.   
 
Discussion 
 The current study is the first to methodically evaluate 
androstenedione’s effects on learning and memory in the middle-aged 
female rodent.  Here, we demonstrate that androstenedione administration 
impairs performance within multiple domains of cognitive function. 
Specifically, in middle-aged OVX rats, androstenedione impaired spatial 
reference memory as well as the ability to maintain performance with 
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increasing memory demand. This was true for both high demand memory 
retention of one item of spatial information (as seen on the DMS task) as 
well as the ability to handle multiple items of spatial working memory 
information (as seen on the WRAM task). The lack of group differences on 
the visible platform task and elevated plus maze suggest that the cognitive 
deficits observed on spatial reference and working memory were not 
attributed to visual impairment or anxiety.  We also confirmed androgen-
induced uterine weight increases, as well as circulating androstenedione 
serum blood levels. Indeed, consistent with previous findings showing 
uterine weight increases after treatment with other androgens (Nantermet 
et al., 2005), androstenedione treatment elevated uterine weights at the 
highest dose, relative to vehicle treatment, in the current study. Androgens 
appear to elevate uterine weight via direct action of androgen receptors 
located in the uterus (Ruizeveld de Winter et al., 1991; Horie et al., 1992), 
an effect not reversed by estrogen receptor antagonists (Schmidt & 
Katzenellenbogen, 1979), thereby suggesting that androstenedione 
effects on the uterus may be due to its androgenic actions rather than 
from aromatized estrogens.  Serum evaluation showed that 
androstenedione levels were higher in both the low and high dose groups 
relative to vehicle, and every rat in the vehicle group produced serum 
androstenedione levels that were undetectable; collectively, these results 
confirm that only the rats in the androstenedione low and high groups had 
the hormone in circulation at levels detectable by the assay used herein.  
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Importantly, both administered doses of androstenedione produced blood 
serum levels comparable to the range of levels achieved in the Acosta et 
al. (2009a) study.  This allows for a controlled cognitive analysis of 
androstenedione at the levels produced in the transitional model, while 
also controlling for any interaction that may occur with presence of the 
residual ovary and any other hormones secreted.   
 Androstenedione dose-dependently negatively impacted spatial 
reference memory on the Morris maze, with a greater swim distance to the 
platform as the dose increased.  It is noteworthy that this impairment 
pervades across all trials and all days of traditional testing; yet, there were 
no group differences in the probe trial. Thus, despite androstenedione-
induced impairments at the high dose on the MM across the three test 
days, rats caught up by the end of testing and eventually learned the task.  
This impairment in learning spatial reference memory was also observed 
in the WRAM.  Rats receiving the high dose of androstenedione 
committed more RM errors compared to those receiving the low dose of 
androstenedione or the vehicle on Trial 2 during the acquisition phase of 
testing (Days 2-6).  This difference was not shown in the second block of 
testing (Days 7-12), indicating that rats receiving the high androstenedione 
dose eventually learned the task similar to rats receiving the low dose or 
vehicle. 
 The current study also found that androstenedione impaired the 
ability to maintain performance as memory demand was increased. This 
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was true for both high demand memory retention of one item of spatial 
information, as well as the ability to handle multiple items of spatial 
working memory information.  On the final two days of testing for WRAM, 
the rats receiving the high dose of androstenedione committed more WMI 
errors on Trial 4, when the working memory load was at its highest, 
compared to those receiving the low dose of androstenedione or vehicle.  
This androstenedione-induced impairment was also shown in the 
significant correlation between WRAM WMI errors on Trial 4 on the last 
two days of testing and androstenedione serum levels.  This is consistent 
with the results from Acosta et al. 2009a, where there was a significant 
correlation between WMI errors and androstenedione serum level with 
more errors correlating with higher circulating androstenedione levels.  On 
the DMS 6 hour delay, there was a high demand for memory retention for 
one item of spatial information.  We found that the rats receiving the 
androstenedione high dose were the only group to commit significantly 
greater errors after the delay compared to baseline.  Taken together, 
these findings suggest that androstenedione at a high physiological level 
impairs the ability to handle learning and memory tasks that require 
greater memory demand.   
The herein study suggests that GABAAR are not involved in 
androstenedione’s detrimental impact on cognition, as we failed to detect 
hormone treatment-related group differences in GAD levels in multiple 
brain regions.  We did, however, find a correlation between GAD levels in 
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the entorhinal cortex and swim distance to the platform in the Morris water 
maze when collapsed across all treatment groups.  Specifically, animals 
that had higher GAD levels in the entorhinal cortex tended to swim a 
greater distance on the MM, thereby suggesting that higher GAD levels in 
the entorhinal cortex are associated with poorer spatial reference memory 
performance.  This is a replication of our previous work showing an 
increase in GAD levels in the entorhinal cortex and impairment in spatial 
reference memory (Braden et al., 2010). The entorhinal cortex and the 
hippocampus are associated with, and play crucial roles in, memory 
processing (Knowles, 1992), which increasing evidence suggests is 
facilitated in part through the GABAergic system (Izquierdo et al., 1993). 
However, the direct mechanism via which androstenedione exerts its 
effects remain to be elucidated.  
Administration of androstenedione may set forth a cascade of 
events leading to a disruption of neuroprotective events through either 
direct action on the androgen receptor, or through its conversion to 
estrone.  Indeed, while the estrogens 17β-estradiol and equilin have been 
found to be neuroprotective (Vegeto et al., 2002; Zhao & Brinton, 2006), 
estrone was found to not have the same neuroprotective effects (Zhao & 
Brinton, 2006).  Thus, estrone’s lack of neuroprotective abilities may be 
playing a role the impairments of memory found in this study. 
Androstenedione may also be impacting cognition through its actions on 
the androgen receptor via its conversion to testosterone.  Indeed, 
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androgen receptors have been located in brain regions important for 
cognition, such as the hippocampus, amygdala, and cortex (Barley et al., 
1975; Sheridan, 1983; Handa et al., 1986; Hajszan et al., 2008).  Future 
research aimed at finding the mechanism(s) responsible for 
androstenedione-induced cognitive impairment could yield valuable insight 
into the hormonal mechanisms relating to the negative cognitive 
consequences of menopause, whereby follicular depletion occurs along 
with retention of the residual ovary, shown in the VCD animal model.  
Future studies to gain insight might include methodically evaluating the 
specific contributions of androstenedione to cognition in female rodent 
models via pharmaceutical manipulations of androgenic stimulation by 
receptor or enzymatic blockade. 
Although androstenedione has not been previously evaluated for 
spatial cognition in older rats, other androgens have been assessed.  The 
most commonly tested androgens have been dihydrotestosterone, 
testosterone, and dehydroepiandrosterone. Research suggests that 
dihydrotestosterone has no impact on spatial reference memory or 
working memory (Raber et al., 2002; Bimonte-Nelson et al., 2003b; Benice 
& Raber, 2009). On the contrary, we and other have shown that 
testosterone treatment has been shown to improve working memory 
(Bimonte-Nelson et al., 2003b), spatial reference memory (Benice & 
Raber, 2009), and avoidance learning and memory (Flood et al., 1995; 
Edinger et al., 2004). The difference between androstenedione’s negative 
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cognitive impact, and testosterone’s positive cognitive impact, may be 
related to the type of estrogen to which these two androgens directly 
synthesize. Testosterone is directly aromatized to estradiol, while 
androstenedione is directly aromatized to estrone.  It may be possible that 
the androstenedione-induced cognitive impairment is in part mediated 
through its conversion to estrone; indeed, androstenedione administration 
significantly increases estrone serum levels (Jasuja et al., 2005).  The 
administration of estrone exogenously appears to negatively affect 
cognition; however, this has only been examined in two studies thus far.  
Work done thus far has found that administration of estrone impaired 
contextual fear conditioning in young adult female rats (Barha et al., 2010) 
as well as working memory on a delay-match-to-sample win-stay task in 
middle-aged female rats (Engler-Chiurazzi, in review).  Research looking 
at the effects of estrone administration on middle-aged and aged rats, 
along with assessing a larger battery of cognitive tasks is needed to gain a 
better understanding of estrone’s impact on cognition.   
 In conclusion, the current study is the first to methodically evaluate 
androstenedione’s effects on learning and memory in the middle-aged 
female rodent model.  Here, we demonstrate that androstenedione 
treatment impaired spatial reference memory, as well as the ability to 
maintain performance as memory demand was elevated.  These results, 
taken with prior findings that higher androstenedione levels correlate with 
poorer working memory in the follicle deplete reproductively senescent 
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ovary intact rat (Acosta et al., 2009a), indicate that androstenedione is a 
key variable impacting memory abilities as menopause ensues.  
Understanding the mechanisms through which androstenedione is 
impairing memory may reveal valuable information toward optimization of 
factors during menopause that could influence cognition. 
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Figure 1. Schematic representation of the experiment. 
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Figure 2. Diagrams of the behavioral mazes used in the experiment.  a. 
Water Radial Arm Maze.  b. Delay Match to Sample Three Choice 
Task.  c. Morris Water Maze.  d. Elevated Plus Maze. 
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Figure 3. Mean (±SE) uterine weights for each group. Uterine weights of the 
Androstenedione High group were greater than those in both the 
Androstenedione Low group [t(14) = 2.47; P = 0.025] and the Vehicle 
group [t(16) = 2.526; P = 0.024]. 
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Figure 4.  a. Mean (±SE) Reference Memory Errors on the WRAM during 
the acquisition phase (Days 2-6) on Trial 2.  Androstenedione High 
group committed significantly more errors compared to both the 
Androstenedione Low group [F(1,14) = 10.654; P = 0.006] and the 
Vehicle group [F(1,16) = 6.974; P = 0.018].  b. Mean (±SE) Working 
Memory Incorrect Errors on the WRAM during the Trial 4 on the last 
two days of testing (Days 11-12).  The Androstenedione High group 
committed significantly more errors compared to both the 
Androstenedione Low group [F(1,14) = 7.862; P = 0.014] and the 
Vehicle group [F(1,16) = 6.673; P = 0.02].  
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Figure  5. Mean (±SE) Total Errors for each group for post-delay trials on 
the DMS.  The Androstenedione High group was the only group to 
make significantly more post-delay errors following the 6 hour delay 
between trials 1 and 2 [t(7) = 3.862; P = 0.006]. 
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Figure  6. Mean (±SEM) swim distance (cm) during MM testing. (a) Swim 
distance across all days and all trials of testing, (b) Swim distance 
across days of testing.  Androstenedione High group swam a 
significantly greater distance to find the platform across all three 
days and all six trials of testing compared to vehicle [F(1,16) = 4.871; 
P = 0.042].  There was also a significant linear trend with swim 
distance increasing as dose of androstenedione increases F(1,2) = 
182.905; P = 0.047]. 
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Figure 7.  a. Mean (±SE) Total Open Arm Entries on the Elevated Plus 
Maze.  There were no group differences.  b.  Mean (±SE) Total Time 
Spent in Open Arms (s) on the Elevated Plus Maze.  There were no 
group differences. 
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Figure 8.  Mean (±SE) swim latency (s) on the Visible Platform.  There 
were no group differences in swim latency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Visible  Platform Latencies
Tr
ial
 1
Tr
ial
 2
Tr
ial
 3
Tr
ial
 4
Tr
ial
 5
Tr
ial
 6
0
10
20
30
40
50
Vehicle
Andro Low
Andro High
Ti
m
e 
(s
)
 46 
 
Figure  9.  a. Mean (±SE) androstenedione serum levels (ng/ml).  Both 
Androstenedione High [t(16) = 4.282; P = .0006] and 
Androstenedione Low [t(16) = 3.846; P = .0014] groups had higher 
androstenedione serum levels than the Vehicle group.  No vehicle 
animal showed any detectable amounts of androstenedione.  b. 
Correlation analysis indicated that higher androstenedione levels 
were associated with more WRAM working memory incorrect (WMI) 
errors on the last two days of testing when the working memory load 
was at its greatest (Trial 4) [r(25) = .609; P = .0007].   
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Figure 10. Correlation analysis indicated that higher GAD levels in the 
right entorhinal cortex were associated with swimming a greater distance 
to find the platform on the MM, collapsed across all days and all trials 
[r(23) = .431; P = .036] . 
 
 
 
 
 
 
 
 
 
  
 48 
 
Table 1. Mean % Vehicle by gel (+SE) of GAD luminescence in the Frontal 
Cortex, Hippocampus, Entorhinal Cortex, Perirhinal Cortex, Cingulate 
Cortex, and Basal Forebrain.  There were no group differences. 
 
       
  
Frontal 
Cortex 
Cingulate 
Cortex 
Basal 
Forebrain 
Perirhinal 
Cortex 
Entorhinal 
Cortex Hippocampus 
GAD Levels            
(% Control)       
Vehicle 
100.00 ± 
6.39 
100.00 ± 
19.50 
100.00 ± 
21.61 
100.00 ± 
9.35 
100.00 ± 
14.26 100 ± 13.48 
Andro Low 
131.48 ± 
27.28 
130.27 ± 
22.53 
90.59 ± 
23.21 
145.00 ± 
20.30 
97.26 ± 
20.86 93.54 ± 7.95 
Andro High 
123.23 ± 
19.59 
109.58 ± 
21.54 
99.11 ± 
9.66 
108.63 ± 
18.22 
92.47 ± 
19.64 96.47 ± 15.05 
 
 
 
 
 
 
